# Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

> **NCT01903681** · PHASE1 · COMPLETED · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Sleep Problems

## Interventions

- **DRUG:** Circadin 2 mg
- **DRUG:** Circadin 10 mg

## Key facts

- **NCT ID:** NCT01903681
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-02
- **Final completion:** 2014-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903681, "Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01903681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*